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Thrombocytopenia may accompany or follow a variety of viral infections including 
influenza (1), measles (2), rubella (3), chickenpox (4), Dengue (5, 6), and cytomega- 
lovirus infections (7). Some human viruses have been shown to interact with circulat- 
ing blood platelets (influenza, rubella). 
Preleukemic thrombocytopenia has been observed in the latency period of leukemia 
after infection by several murine leukemia viruses, especially in Friend leukemia virus 
(8)  and Rauscher murine leukemia virus (RMuLV) 1 infections (9).  In the RMuLV 
model,  thrombocytopenia develops  early  after  infection  and  lasts  throughout  the 
latency period. Platelet counts return to normal before the development of erythro- 
leukemia, after which they fall again.  In the case of spontaneous leukemia in AKR 
mice, thrombocytopenia has also been observed during the weeks preceding devel- 
opment of leukemia (10). It has been suggested that some thrombocytopenia-inducing 
viruses,  especially  leukemia  viruses,  could  replicate  in  the  cytoplasm  of marrow 
megakaryocytes, cells from which circulating blood platelets are shed. Indeed, budding 
type C  viral particles have been detected by electron microscopy after infection by 
Newcastle  disease  virus  (11),  Moloney's, Gross',  Friend,  and  Manaker  viruses  (12), 
RMuLV (9), and BL/F virus (13). 
In  addition,  it  has been  demonstrated  that  susceptibility to viral-induced leuke- 
mogenesis  in  mice  is  under  genetic control  and  that  the  major histocompatibility 
complex (H-2) appears to be specifically involved (14-17). The gene(s) controlling the 
susceptibility to Friend leukemia virus seems to be related to the D region of the H-2 
complex (18). It has also been shown that susceptibility to leukemogenesis is inherited 
as a  dominant trait  (14,  19). However, the mechanisms of action of this gene(s) and 
the nature of the gene product are not yet defined. 
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1Abbreviatzons  used  in  this  paper:  CATCH,  Ca  ++-  and  Mg*+-free  Hanks'  balanced  salt  solution  with 
adenosine,  theophylline,  trisodium  citrate  and  tlepes  buffer;  FITC,  fluorescein  isothiocyanate;  PBS, 
phosphate-buffered saline; RMuLV, Rauscher routine leukemia virus. 
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The  aim  of this  work  was  first  to  determine if preleukemic  thrombocytopenia 
induced by  RMuLV  was  also  under genetic  control,  and  second  to  evaluate  the 
possible expression of viral antigens on megakaryocytes and platelets in infected mice 
and to investigate the H-2 dependency of these antigenic expressions. The immediate 
interactions between  platelets  and  RMuLV  have  been  considered  particularly in 
relation to the genetic susceptibility to leukemogenesis. 
Materials and Methods 
Mice.  6-8-wk-old female BALB/c and C57BL/6 mice were purchased from IFFA CREDO 
Laboratories, Centre de Recherche et d'Elevage des Oncins, St. Germain-sur-l'Arbresle,  France. 
CBA, C3H, and DBA/2 mice were purchased from Charles River Breeding Laboratories, Inc., 
Elbeuf, France. BXSB mice were obtained from The Jackson Laboratory, Bar Harbor, ME. 
B10.D2,  B10.BR, B10.G, B10.A(4R), B10.A(5R), B10.T(6R), B10.HTG, C57BL/10ScSn, and 
DBA/1 mice were purchased from Olac Laboratories, Oxon, England. (DBA/2 ×  BXSB)  F1, 
(C3H ×  BXSB) F1, and (BALB/c × C57BL/6)F1 hybrid mice were obtained by local breeding. 
Virus.  Purified RMuLV-JLS V9 was obtained from Frederick Cancer Institute, Frederick, 
MD.  The  virus (1012 viral particles/ml)  was  injected intravenously or  intraperitoneally at 
dilutions varying from 1:5 to 1:2 ×  105 in 0.2 ml sterile phosphate-buffered saline (PBS), 0.01 
M, pH 7.2. 
Antisera.  Goat anti-Rauscher gp70 antiserum was a gift from Dr. J. H. Elder, Scripps Clinic 
and Research Foundation, La Jolla, CA. Fluorescein isothiocyanate (FITC) rabbit anti-goat 
IgG was obtained from Nordic, Lausanne, Switzerland.. 
Rabbit anti-Rauscher p30 antiserum was  kindly provided by Dr.  Louis de Saint Georges, 
Centre d'Etude sur l'Energie Nucl~aire, Mol, Belgium. FITC-goat anti-rabbit IgG (Behring, 
Hoechst-Pharma AG, Zurich, Switzerland) was used for indirect immunofluorescence. 
Blood  Platelet  Counts.  Blood  was  obtained  from  the  retroorbital  plexus  by  using 20  ~1 
microcapillaries and was immediately diluted 1  : 100 in Unopette kits (Becton, Dickinson & Co., 
Basel, Switzerland). The diluted blood sample was allowed to settle for 20 min in an "improved 
Neubauer" hematocytometer and platelets were counted under a Leitz phase-contrast micro- 
scope  (E. Leitz, Inc., Rockleigh, N  J) at 400 ×  magnification. 
Bone Marrow Samples.  Bone marrow was harvested from mouse femurs and tibias in CATCH 
medium (20), made of Ca  ++- and Mg++-free Hanks' balanced salt solution (Gibco AG, Basel, 
Switzerland) containing 10  -3 M adenosine, 2 ×  10  -3 M theophylline, 3.8% trisodium citrate, 25 
mM Hepes buffer, and 3.5% bovine serum albumin fraction V  (all  from Sigma Chemicals, 
Zurich, Switzerland). This medium has been shown to prevent the rapid vacuolization and 
degranulation of megakaryocytes  observed  when  other  media  are  used  (20). The  marrow 
specimens were converted into a single-cell suspension by repeated aspiration-extrusion from a 
Pasteur pipette.  For immunofluorescence studies, megakaryocyte-enriched populations were 
obtained by  discontinuous gradient  centrifugation in  Percoll  (Pharmacia  Fine Chemicals, 
Zurich,  Switzerland)  (modified  from  Rabellino et  al.  [21]). For  cell  transfer experiments, 
megakaryocytes  were  further  isolated  by  velocity  sedimentation.  Purity  of  the  final  cell 
suspension was 90%. 
Immunofluorescence Studies  on Megakaryocytes and Platelets.  The megakaryocyte-enriched popu- 
lations (3-6% of megakaryocytes) were washed twice (300 g, 10 min, 4°C) in CATCH medium 
and spun on a cytocentrifuge (Shandon Southern Instruments Inc., Sewickley, PA). The smears 
were fixed in acetone at -20°C for  10 rain and incubated for 30 min at 37°C with goat anti- 
gp70 and rabbit anti-p30 antibodies. Normal goat serum, normal rabbit serum, or PBS were 
used as controls. The smears were washed three times in PBS 0.01 M, pH 7.2 and reincubated 
in the same conditions with the corresponding FITC conjugate. After three further washes  in 
PBS,  the slides  were  mounted and examined under a  Leitz Orthoplan immunofluorescence 
microscope.  Isolated platelets were obtained by differential centrifugation as follows: citrated 
blood (9 vol blood/1 vol 3.13% sodium citrate) was first  centrifuged at  1,600 g for 4 min at 
room temperature. The platelet-rich plasma was then centrifuged at 2,200 g for 10 min at room 
temperature to obtain the platelet pellet. This pellet was then washed three times in EDTA- 
PBS (0.009 M Na2 EDTA, 0.0264 M Na~HPO4-2H20, 0.14 M NaCI), pH 6.9. After fixation in 1030  GENETIC  CONTROL  OF  VIRUS-INDUCED  THROMBOCYTOPENIA  !l 
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Fro.  1.  Thrombocytopenia  after  intravenous  injection  of  RMuLV.  It-2  a  (BALB/c,  DBA/2, 
B10.D2),  H-2 k  (C3H,  CBA,  BI0.BR),  H-2 h  (C57BL/6,  BXSB,  C57BL/10),  and  H-2  q  (DBA/2, 
B 10.G)  mice were injected intravenously with 0.2 ml RMuLV  (1:20) on day 0. Blood platelets were 
counted at  l  h,  l  d, 4 d~ and 9 d  after the injection of RMuLV.  Each point represents an individual 
mouse (B6 =  C57BL/6;  B10 =  C57BL/10). 
suspension  by paraformaldehyde (1% wt/vol in PBS)  and three further washes,  the platelets 
were analyzed by indirect immunofluorescence, using anti-gp70 and anti-p30 antibodies. 
Assay for  gp70.  Concentrations  of gp70  in  sera  of mice  injected  with  RMuLV  were 
determined by their capacity to inhibit the binding of goat anti-feline leukemia virus antibody 
to  125I-labelled gp70  from  RMuLV.  The  details  of this  radioirnmunoassay  were  previously 
described (22). 
Results 
H-2 Dependency of RMuL V-induced Thrombocytopenia.  The occurrence of preleukemic 
thrombocytopenia  after  the  infection  of mice with  RMuLV  was  first  confirmed  in 
BALB/c mice susceptible to RMuLV-induced leukemia. To study the kinetics of this 
thrombocytopenia in more detail,  BALB/c mice were injected intraperitoneally  with 
0.2 ml RMuLV-JLS.V9 diluted  1:20 in sterile PBS. Blood samples for hematological 
parameters  were collected sequentially.  Thrombocytopenia developed within  4  d.  A 
rebound  phenomenon  was observed  10-14 d  after  intraperitoneal  injection.  During 
that  period, other cell counts were normal. The same experiment  was performed on 
two strains  of mice that  are  either  susceptible  (BALB/c)  or resistant  (C57BL/6)  to 
leukemogenesis.  Several dilutions (1:5,  1:10, 1:20,  1:200,  1:2 ×  103, 1:2 ×  104, and  1:2 
×  10  ~)  of RMuLV  were injected  intraperitoneally  into BALB/c (H-2 d) and C57BL/ 
6  (H-2  b) mice. Platelet counts taken 4 d  after the injection showed that the degree of 
thrombocytopenia  was  dose  dependent  in  BALB/c mice with  virus  dilutions  from 
1:20 to  1:2 ×  105. When virus was injected into BALB/c mice at dilutions of 1:5 and GRAU,  PUTHAVATHANA,  IZUI, AND  LAMBERT  1031 
TABLE  I 
Susceptibility  to RMuL V-induced Thrombocytopenia in B10 Congenic and 
B l O Intra-H-2-recombinant  Mice 
H-2-TIa complex 
Strains  I  Qa 
K  S  G  D 
A  B  J  E  C  3  2  1 
Percent 
Throm-  decrease 
bocyto-  in plate- 
Tla  penia  let 
counts* 
BI0.A(3R)  b  b  b  b  k  d  d  d  d  a  Yes  39.0 
B10.A(4R)  k  k  b  b  b  b  b  b  b  a  a  b  No  3.8 
B10.A(5R)  b  b  b  k  k  d  d  d  d  a  a  a  a  Yes  49.3 
B10.T(6R)  q  q  q  q  q  q  q  ?  d  a  a  a  a  Yes  43.2 
B 10,HTG  d  d  d  d  d  d  d  ?  b  b  b  No  1.5 
B10  b  b  b  b  b  b  b  b  b  a  a  b  b  No  0.1 
B10.D2  d  d  d  d  d  d  d  d  d  a  a  b  c  Yes  31.4 
B 10.BR  k  k  k  k  k  k  k  k  k  b  b  a  a  Yes  43.4 
BI0.G  q  q  q  q  q  q  q  q  q  No  3.4 
* Platelets  were counted  l  d  after  intravenous injection  of 0.2  ml  RMuLV  (diluted  1:20). Results are 
expressed as percentage of decrease in platelet counts compared with preinjection levels  (mean of five to 
seven mice in each group). BI0, C57BL/10. 
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Fie.  2.  Kinetics of expression of viral antigens, gp70 and p30, in bone marrow megakaryocytes of 
BALB/c mice. RMuLV (0.2 ml, 1:20) was injected intraperitoneally on day 0. Results are expressed 
as the percentage of positive megakaryocytes for either gp70 or p30 antigens (detected by indirect 
immunofluoreseence). MKC, megakaryocytes. 
l:10, the thrombocytopenia was not more pronounced than with  1:20, but the kinetics 
of the response were different; the thrombocytopenia occurred  1 d  after the injection 
of the virus and the rebound  phenomenon  was observed after 4  or 5  d.  In contrast, 
platelet counts remained unaffected at any dilution in C57BL/6  mice. 
Thrombocytopenia after RMuLV  injection was then evaluated in H-2 d (BALB/c, 
DBA/2, and B10.D2)  and H-2  k (C3H, CBA, and B10.BR)  mice, which are known to 
be  susceptible  to  leukemia  induction  by  RMuLV,  as  well  as  in  H-2 b  (C57BL/6, 1032  GENETIC CONTROL  OF  VIRUS-INDUCED THROMBOCYTOPENIA 
FiG.  3.  (A)  Immature  megakaryocytes  exhibiting peripheral  staining  for gpT0 antigen  (indirect 
immunofluorescence).  Day  12 after intraperitoneal injection  of 0.2 ml RMuLV (1:20) (x 630). (B) 
Mature megakaryocytes  exhibiting reticular staining for gp70 amigen. Day 16 after intraperimneal 
injection  by  RMuLV  (same  dose)  (X 63(/).  (C)  Mature  megakaryocytes  releasing  cytoplasmic 
fragments.  Day  16 after intraperitoneal injection  of RMuLV (same dose) (x 400). (D) Circulating 
Mood ptateIets  exhibiting gp70  antigen.  Day 22 after intraperitoneal  injection  of RMuLV (same 
dose) (X 630). GRAU, PUTHAVATHANA, IZUI, AND LAMBERT  1033 
BXSB,  C57BL/10ScSn)  and  H-2  q  (DBA/1,  B10.G)  mice,  which  are  resistant  to 
leukemia induction.  Both intraperitoneal and intravenous injections were performed, 
using  0.2  ml  1:20  diluted  RMuLV.  The  kinetics  of  thrombocytopenia  differed 
according to the route of injection. After intraperitoneal injection, thrombocytopenia 
developed within 3-4 d; the rebound phenomenon occurred after 10-14 d in the H-2  d 
and  H-2  k strains.  However, intravenous  injection  induced  thrombocytopenia within 1034  GENETIC  CONTROL OF VIRUS-INDUCED  TttROMBOCYTOPENIA 
a few minutes in H-2  d and H-2  k strains and platelet counts returned to pretreatment 
levels within 9 d (Fig.  1). Whatever the route of injection, no change in platelet counts 
was  observed  in  the  H-2  b and  H-2  q strains  examined.  0.2  ml  buffer alone  did  not 
induce any decrease in platelet counts even within the first  minutes after intravenous 
injection.  No relation  between  Tla  regions and  thrombocytopenia was  observed  in 
these various strains of mice. 
Because susceptibility to virus-induced leukemogenesis is known to be inherited as 
a  dominant  trait  (4),  the  occurrence of thrombocytopenia after  RMuLV  injection 
was investigated in F1 hybrid mice from "sensitive" and "resistant" parents. Intrave- 
nous injection of 0.2 ml RMuLV (diluted 1:20) was performed in (BALB/c X C57BL/ 
6)F1,  (DBA/2  X  BXSB)F1, and  (C3H  X  BXSB)F1 female mice. Thrombocytopenia 
was  observed  in  each  of these  three  hybrids:  (BALB/c  ×  C57BL/6)F1  RMuLV- 
injected: 0.59 +  0.07 ×  106 platelets/mm3; control:  1.39 +  0.08 ×  106 platelets/mma; 
(DBA/2  ×  BXSB)F1  RMuLV-injected:  1.03 +  0.20  X  106 platelets/mma;  control: 
1.60 +  0.07  X  106 platelets/mma;  (C3H  X  BXSB)F1 RMuLV-injected: 0.71  ___ 0.03 
X  106 platelets/mma; control:  1.41 +_ 0.08 ×  106 platelets/mm 3. 
To  further  investigate  the  H-2  dependency  of  Ihrombocytopenia  induction, 
RMuLV was injected into BI0 intra-H-2-recombinant mice. Table I shows the origin 
of H-2 regions of the mice investigated, together with their susceptibility to RMuLV- 
induced  thrombocytopenia.  All  the  mice  with  allele  d  at  the  D-end  developed 
thrombocytopenia.  Each strain  susceptible  to  thrombocytopenia induction  differed 
from  its  resistant  counterpart  only  at  the  D  region  of the  H-2-TIa complex.  For 
example, as in B10.T(6R)  mice, even if the d allele is present only at the D-end and 
if the rest of H-2 complex is made of "resistant" alleles,  thrombocytopenia developed 
with the same pattern as in H-2  d or H-2  k mice. In contrast, in B10.HTG, which have 
b allele at  the D-end but d allele in  the other regions of the H-2 complex, thrombo- 
cytopenia did not occur. 
Expression  of RMuL V Antigens on Megakaryocytes  and its Relation to H-2 Complex.  The 
relationship between the occurrence of thrombocytopenia and possible viral antigen 
expression on marrow megakaryocytes was then investigated.  RMuLV was injected 
intraperitoneally  in  BALB/c mice at  a  dose sufficient  to induce thrombocytopenia 
(1:20 dilution,  0.2  ml/mouse).  Then,  at  specific intervals  thereafter,  groups of five 
mice  were  killed  and  bone  marrow  was  harvested  from  4  to  35  d  after  infection. 
Megakaryocyte-enriched fractions prepared by discontinuous gradient centrifugation 
were smeared  and  analyzed by indirect  immunofluorescence using antisera  specific 
for gp70 or p30 antigens. On each slide,  at least 2.5 ×  102 megakaryocytes at different 
maturation stages were examined.  Viral antigens were detectable from the 4th d  of 
infection and the frequency of viral antigen-carrying-megakaryocytes increased pro- 
gressively until day 35. In general, the appearance of gpT0 antigen in megakaryocytes 
preceded that of p30 antigen  (Fig.  2). 
As can be seen in Fig. 3 A and B, gp70 antigen was detectable in both immature 
and mature megakaryocytes. However, the pattern of staining differed in immature 
and mature cells: young cells exhibited a peripheral pattern (cytoplasmic membrane) 
(Fig.  3 A), whereas fully mature megakaryocytes, with a well-developed demarcation 
membrane system, were stained  with  a  reticular  pattern  throughout the cytoplasm 
(Fig. 3 B). The pattern of staining for p30 was essentially the same. This suggested the 
presence of viral antigens throughout the demarcation membrane system. It can also GRAU,  PUTHAVATHANA,  IZUI,  AND  LAMBERT  1035 
be  seen  that  cytoplasmic  fragments  of megakaryocytes  (Fig.  3C),  which  would 
eventually give rise to circulating blood platelets, carried viral antigens. In fact, when 
the circulating blood platelets were examined for the presence of gp70 antigen, ~30% 
of them were found to be positively stained (Fig. 3 D). 
Because evidence of H-2-dependent susceptibility to thrombocytopenia induction 
was provided by the previous experiments, the expression of gp70 and p30 antigens 
was  investigated in various strains of mice. H-2  d (BALB/c, DBA/2,  B10.D2),  H-2  k 
(C3H, CBA, B10.BR), H-2  b (C57BL/6, BXSB, C57BL/10ScSn), and H-2  q (DBA/1, 
B10.G) mice received intraperitoneal injections of 0.2 ml  1:20 diluted RMuLV. The 
megakaryocytes harvested 16 d after injection were examined for the presence of viral 
antigens  gp70  and  p30  (Fig.  4).  Only  murine  strains  with  either  H-2  d  or  H-2  k 
haplotype exhibited positive staining for both viral antigens in their megakaryocytes, 
although some differences were observed in the magnitude of viral antigen expression. 
On the other hand, megakaryocytes from resistant strains of mice (H-2  b or H-2  q mice) 
did not  express any viral antigens.  In similar experiments,  (BALB/c ×  C57BL/6), 
(C3H  X  BXSB),  and  (DBA/2  ×  BXSB)F1  hybrids  also  expressed  gp70  and  p30 
antigens after injection of RMuLV, which correlates with the inheritance of suscep- 
tibility to thrombocytopenia. 
The  ability  to  transfer  RMuLV  infection  with  megakaryocytes  isolated  from 
infected mice was assessed.  BALB/c mice were infected by intraperitoneal injection 
with  RMuLV  (1:20).  16  d  later,  mice  were  killed  and  bone  marrow  harvested. 
Megakaryocytes were isolated from bone marrow, and the megakaryocyte suspension 
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FIG. 4.  Expression of viral antigens, gp70 and p30, in bone marrow megakaryocytes of various 
strains of mice. The percentage of megakaryocytes positively stained for gp70 or p30 were evaluated 
16 d after intraperitoneal injection of 0.2 ml RMuLV (1:20). MKC, megakaryocytes. 1036  GENETIC  CONTROL  OF  VIRUS-INI)UCEI) TttROMBOCYTOPENIA 
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FIG.  5,  Development of thrombocytopenia by injection of megakaryocytes from RMuLV-infected 
mice.  Megakaryocytes were purified from bone marrow of BAI,B/c mice infected by intraperitoneal 
injection  of 0.2  ml  RMuLV  (1:20)  sixteen  d  before.  I0  "~  MKC  were injected  intravenously into 
normal  BALB/c  mice on  day  0  (O),  As a  control,  10  '~  MKC  from  normal  BALB/e  mice  were 
injected  into syngeneic mice (C)). Each point represents individual  platelet counts; bars represents 
means of platdet counts. MKC, megakaryocytes. 
(90% pure)  was injected after three washes in CATCH medium into the tail  vein of 
five  normal  BALB/c  mice  (10  '~  megakaryocytes  per  mouse  in  0.4  ml  CATCH). 
Approximately 80% of the megakaryocytes in this preparation were positively stained 
for gp70 antigen.  No other cell  was positive for viral antigens.  Megakaryocytes were 
similiarly  prepared  from  normal  BALB/c mice and  injected  in  other normal  BALB/c 
mice as control. All the BALB/c mice that were injected with megakaryocytes isolated 
from  infected  animals  developed  thrombocytopenia within  a  week  (Fig.  5).  This 
thrombocytopenia lasted 6 mo, and during that  time serum gp70 levels  rose to 49.5 
+__ 11.9/ag/ml (normal values, 0.9 +_ 0.2 ffg/ml). During the 7th mo, erythroleukemia 
developed.  In  contrast,  no change  in  platelet  counts or  in  serum  gp70  levels  were 
detected,  and  leukemia  did  not  develop  in  BALB/c  mice  injected  with  normal 
syngeneic megakaryocytes. 
Discussion 
In this study, we have shown that thrombocytopenia, which is known to occur in 
the preleukemic phase of RMuLV-induced disease  (9),  is under genetic control and 
is more specifically related to the H-2 complex. Both intraperitoneal and intravenous 
injection  of RMuLV were  used:  in  each  case only H-2  d and  H-2  k mice developed 
thrombocytopenia, whereas  H-2  b and  H-2  q mice did  not.  Unlike  the  thrombocyto- 
penia due to Friend leukemia virus infection, which occurs only 7 d after intravenous 
injection  (8),  thrombocytopenia is observed within  a  few minutes after intravenous 
injection of RMuLV. Such a  rapid development of thrombocytopenia is most likely 
due to platelet  destruction  in  the periphery, possibly the result of direct  interaction 
between platelets and viral particles. 
The  study  of  the  response  to  RMuLV  in  various  strains  of  mice,  and  most 
significantly in B 10-congenic mice, suggests that the susceptibility to RMuLV-induced 
acute thrombocytopenia is controlled by a gene(s)  closely linked to the H-2 complex. 
Furthermore, results using B10-intra-H-2-recombinant mice indicate that the gene(s) 
coding for susceptibility  to thrombocytopenia is associated with the D  region of the 
H-2 complex. The H-2D  d allele is associated with susceptibility to thrombocytopenia GRAU, PUTHAVATHANA, IZUI, AND LAMBERT  1037 
induction, whereas the H-2D  b allele confers resistance. One should note that neither 
the Qa 3, 2, 1, nor the Tla regions are involved in conferring susceptibility to RMuLV- 
induced thrombocytopenia. 
Our results suggest that the gene(s) controlling susceptibility to RMuLV-induced 
thrombocytopenia is the same gene(s)  (or closely linked to the gene) that controls the 
susceptibility to leukemogenesis. This hypothesis  is supported  by the  following evi- 
dence.  First,  RMuLV  induces  thrombocytopenia only in leukemia-susceptible H-2  a 
and H-2  k mice but not in leukemia-resistant H-2  b and H-2  q mice. Second, as in the 
case of the gene controlling leukemogenesis (14,  19), the susceptibility to thrombocy- 
topenia is inherited as a dominant trait, as suggested by the results in F1 hybrids. 
Type C  viral particles have been detected by electron microscopy in the cytoplasm 
of marrow and spleen  megakaryocytes after injection  by RMuLV  (12,  23,  24).  We 
have shown  in  this  study  that  viral  antigens  are  expressed on  megakaryocyte cell 
membranes. The glycoprotein of the virus envelope (gp70), as well as the core protein 
(p30),  are  detectable  on  the  surface  and  throughout  the  demarcation  membrane 
system of megakaryocytes. The presence of p30 antigen together with gp70 antigen is 
indirect  evidence  of viral  replication  inside  these  cells,  because  core  proteins  are 
produced during active viral replication. More directly, the presence of infective virus 
in megakaryocytes is suggested by the fact that isolated megakaryocytes from infected 
mice,  when  injected  in  normal  syngeneic  mice, can  trigger thrombocytopenia and 
induce erythroleukemia. It is striking that in the initial phase of RMuLV infection, 
megakaryocytes are the only marrow cells exhibiting viral antigens. These observations 
suggest that megakaryocytes may be among the first sites of RMuLV replication. 
The infection of megakaryocytes by RMuLV appears to be governed by the same 
gene that controls susceptibility to thrombocytopenia, because only those megakary- 
ocytes from mice developing thrombocytopenia express viral antigens. The preferen- 
tial expression of viral antigens in megakaryocytes suggests the existence of a receptor- 
like molecule for RMuLV on megakaryocyte cell membranes. This molecule would 
be the gene product of the  H-2 linked  gene that  confers susceptibility to RMuLV- 
induced thrombocytopenia as well as leukemogenesis. In view of the fact that platelets 
and megakaryocytes share most of their membrane components, it is probable that 
platelets would  also bear this H-2-1inked receptor-like molecule on their membrane. 
This  would  be consistent  with  the  rapid  in  vivo effect of RMuLV  on  platelets  of 
susceptible mice after intravenous injection. This mechanism could be of relevance in 
the development of virus-induced leukemia in mice. 
Summary 
Acute  thrombocytopenia  and  megakaryocyte  infection  have  been  investigated 
during the preleukemic phase of the disease induced by the Rauscher murine leukemia 
virus  (RMuLV)  in  mice.  Injection of RMuLV,  either intravenously or intraperito- 
neally, rapidly  induced  thrombocytopenia, possibly as a  result  of direct  interaction 
between platelets and viral particles. The susceptibility to this acute thrombocytopenia 
was genetically controlled and was inherited as a dominant trait. Murine strains with 
H-2  d  or  H-2  k  haplotype,  which  are  susceptible  to  the  induction  of leukemia  by 
RMuLV,  developed  thrombocytopenia, whereas  leukemia-resistant  H-2  b and  H-2  q 
strains  of mice  failed  to  develop  thrombocytopenia.  Using  B10  H-2-congenic  and 
intra-H-2-recombinant mice, it was shown that the susceptibility to RMuLV-induced 1038  GENETIC  CONTROL  OF VIRUS-INDUCED THROMBOCYTOPENIA 
thrombocytopenia was controlled by gene(s) in or closely linked to the D  region of the 
H-2 complex, 
Megakaryocytes may be one of the first sites for the replication of RMuLV.  Indeed, 
among  bone  marrow  cells, only  megakaryocytes expressed  viral  antigens  gp70  and 
p30 during the initial phase of RMuLV  infection. In addition, megakaryocytes from 
infected mice were able to transfer preleukemic thrombocytopenia as well as leukemia 
in  syngeneic  mice.  The  infection  of  megakaryocytes  by  RMuLV  appears  to  be 
genetically controlled in a manner similar to the induction of thrombocytopenia, since 
only the megakaryocytes from  mice developing thrombocytopenia were  infected by 
RMuLV.  These  results indicate that  the gene(s)  governing the induction of throm- 
bocytopenia by RMuLV  may be the same gene(s)  (or closely linked to the gene) that 
controls  the  susceptibility  to  leukemogenesis,  and  would  be  consistent  with  the 
expression of the gene product, presumably a  receptor-like molecule for RMuLV,  on 
platelet and megakaryocyte membranes. 
We thank Mrs. M. Devouge for her secretarial assistance. 
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